Alto Neuroscience (ANRO) Convertible Debt (2024 - 2026)

Alto Neuroscience has reported Convertible Debt for 3 years, with the latest figure at $2.3 million in Q1 2026.

• Quarterly Convertible Debt rose 92.82% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 92.82% YoY) and the FY2025 annual result came in at $2.2 million, up 70.78% from the prior year.
• Convertible Debt climbed to $2.3 million in Q1 2026 per ANRO's latest filing, from $2.2 million in the prior quarter.
• Over five years, Convertible Debt peaked at $2.3 million in Q1 2026 and troughed at $1.2 million in Q1 2025.
• A 3-year average of $1.8 million and a median of $2.0 million in 2025 frame the typical range for Convertible Debt.
• The sharpest annual moves came in 2025 and 2026: Convertible Debt surged 63.64% in 2025, then jumped 92.82% in 2026.
• Over 3 years, Convertible Debt stood at $1.3 million in 2024, then surged by 70.78% to $2.2 million in 2025, then rose by 4.85% to $2.3 million in 2026.
• According to Business Quant data, Convertible Debt over the past three periods registered $2.3 million, $2.2 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.